Ken Griffin Cure Vac N.V. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.74 - $3.79 $5,480 - $7,580	2,000 Added 9.43%	23,200 $68,000
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.99 $462 - $998	-200 Reduced 0.93%	21,200 $72,000
Q1 2024 May 15, 2024	SELL	$2.94 - $4.34 $284,886 - $420,546	-96,900 Reduced 81.91%	21,400 $64,000
Q4 2023 Feb 14, 2024	BUY	$3.96 - $6.41 $23,364 - $37,819	5,900 Added 5.25%	118,300 $498,000
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $258,050 - $427,569	39,700 Added 54.61%	112,400 $767,000
Q2 2023 Aug 14, 2023	SELL	$6.69 - $12.25 $36,795 - $67,375	-5,500 Reduced 7.03%	72,700 $757,000
Q1 2023 May 15, 2023	SELL	$6.38 - $12.5 $405,768 - $795,000	-63,600 Reduced 44.85%	78,200 $545,000
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $127,650 - $188,700	22,200 Added 18.56%	141,800 $855,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $412,896 - $841,248	-55,200 Reduced 31.58%	119,600 $942,000

12.1M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $516M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.